Restructuring Supports RYTELO® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced a strategic restructuring plan intended to position the Company for long-term value creation for patients and shareholders and improve its financial d ...

Core Insights - Proactive provides fast, accessible, and actionable business and finance news content to a global investment audience [2] - The company focuses on medium and small-cap markets while also covering blue-chip companies and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, mining, oil and gas, and emerging technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Insights - TME Pharma has undergone a reorganization to a lower-cost outsourced staffing model, which is expected to lead to significant cost reductions starting in the second half of 2025 [2][3] - The company raised €1.7 million through a bond issuance in May 2025 and an additional €500,000 in August 2025, indicating investor confidence in the new strategy [2] - TME Pharma is committed to continuing the research and development of its lead assets, NOX A12 and NOX E36, while also exploring investments in potentially profitable businesses [3][11] Financial Performance - In the first half of 2025, TME Pharma recorded a turnover of €27,000 compared to €0 in the same period of 2024, with a net loss of €2.1 million, an improvement from a loss of €3.2 million in H1 2024 [4] - The cash position as of June 30, 2025, was €2.06 million, down from €2.70 million on June 30, 2024, with negative equity of €570,000 [4] - Financial visibility extends to May 28, 2026, with the potential to negotiate an extension of maturing debt to improve financial stability [4] Leadership and Strategy - Diede van den Ouden was appointed as the new CEO in June 2025, and he emphasizes a collaborative transition with the previous leadership [5] - The company is focusing on a strategic restructuring to unlock the value of its lead assets, NOX-A12 and NOX-E36, while also exploring acquisitions and partnerships in stable, profitable businesses [7][11] - TME Pharma aims to create a fundamentally profitable corporate structure where revenues from non-core activities will support the development of its patented drug candidates [11] Research and Development - NOX-A12 is currently in a Phase 1/2 clinical trial for glioblastoma, with FDA Fast Track Designation and orphan drug designation in the US and Europe [6][8] - NOX-E36 is being evaluated for ophthalmic diseases, focusing on well-tolerated therapies with anti-fibrotic effects [6] - The company is also planning a Phase 2 study for NOX-A12 in combination with other treatments for metastatic pancreatic cancer [9]

Group 1 - AGM Group Holdings Inc. (AGMH) experienced a significant after-hours trading surge of 158.74%, rising to $5.77 from a closing price of $2.23 on Thursday, following the filing of Form 6-K with the SEC [1][5] - The filing disclosed the completion of the sale of AGM's Hong Kong subsidiary, Nanjing Lucun Semiconductor Co. Ltd., to Hong Kong Giant Electronics Co., Limited for $57.45 million on May 7, with Nanjing Lucun primarily engaged in manufacturing advanced hardware and computing equipment [2] - Investors perceive the asset sale as transformational, providing cash proceeds exceeding 13 times AGM's current market capitalization, with unaudited pro forma financial statements indicating continuing operations generated $3.41 million in net income for 2024, alongside revenues of $32.04 million [3] Group 2 - The sale represents a significant transaction for AGM, which has a market value of $4.29 million and a price-to-earnings ratio of 0.32, with the stock showing high volatility, fluctuating between $1.09 and $108.48 over the past year [4] - AGM's stock has seen a dramatic decline of 97.05% for 2025, with a year-to-date peak of $75.50 on December 31, and a closing price of $2.23 yesterday, marking a 97.03% decline from the peak [4] - During regular trading hours, AGMH closed down 5.91% before the after-hours reversal, indicating short-term upward movement according to Benzinga's Edge Stock Rankings [5]

Core Viewpoint - Golden Triangle Ventures, Inc. (GTVH) has executed a binding Memorandum of Understanding (MOU) that signifies a new leadership direction, high-growth assets, and a long-term strategic vision for the company [1][2]. Group 1: Strategic Developments - The MOU will enable GTVH to integrate a portfolio of fast-moving consumer brands and a distribution company with over $20 million in annual revenue, aimed at unlocking shareholder value and enhancing operational efficiency [2][5]. - Javier Leal has been appointed to lead the company, bringing a strong track record in building businesses and merging his portfolio into GTVH [3][7]. - The outgoing CEO, Steffan Dalsgaard, will transition to an advisory role for 60 days to ensure a smooth handover and the successful spin-off of Lavish Entertainment [4][7]. Group 2: Financial and Operational Focus - GTVH's noteholder has committed funding for acquiring a new publicly traded company that will include Lavish Entertainment and Destino Ranch, with existing shareholders set to receive an equity dividend in the new entity [5][6]. - The company plans to spin out LE Logistics and non-performing legacy assets to concentrate on high-growth opportunities, thereby streamlining operations and focusing on profitability [6][7]. Group 3: Future Outlook - The restructuring is described as a relaunch, with the potential for two powerful narratives unfolding simultaneously for shareholders [7]. - Additional details regarding leadership changes and dividend instructions are expected to be released in the coming weeks [7].